Amazon will sell exclusive line of medical products

In another step into the healthcare arena, Amazon has teamed up with a health brand consultancy company to sell exclusive medical products on the Amazon marketplace, CNBC reported.

The partnership with Arcadia Group will offer products such as blood pressure cuffs and glucose monitors, according to CNBC, and follows Amazon’s interest in selling exclusive lines of products and brands. The new brand of medical products is called Choice.

While the products will be exclusive to Amazon, Arcadia Group has also developed other health brands for Walmart and others, CNBC reported.

Amazon already sells over-the-counter medications and operates as a platform for medical device sales through its Amazon Business branch. The company is actively making moves in healthcare elsewhere, including teaming up with Berkshire Hathaway and JPMorgan Chase & Co. to create a new entity to lower healthcare costs for the employees of all three companies.

Amazon has also opened up healthcare clinics for it employees at its Seattle headquarters. Its Alexa voice technology platform also is increasingly finding new healthcare-related solutions.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.